{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T07:35:18Z","timestamp":1771054518618,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81271979"],"award-info":[{"award-number":["81271979"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"crossref","award":["2010CB529400"],"award-info":[{"award-number":["2010CB529400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s10549-015-3290-x","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T19:28:40Z","timestamp":1429644520000},"page":"705-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-\u03baB signaling pathways"],"prefix":"10.1007","volume":"149","author":[{"given":"Hongkai","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyun","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongwei","family":"Chu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"issue":"20 Pt 2","key":"3290_CR1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s\u20136249s","journal-title":"Clin Cancer Res"},{"issue":"12","key":"3290_CR2","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0959-8049(03)00422-2","volume":"39","author":"J Engel","year":"2003","unstructured":"Engel J, Eckel R, Kerr J, Schmidt M, Furstenberger G, Richter R, Sauer H, Senn HJ, Holzel D (2003) The process of metastasisation for breast cancer. Eur J Cancer 39(12):1794\u20131806","journal-title":"Eur J Cancer"},{"issue":"10","key":"3290_CR3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1158\/1535-7163.MCT-07-0234","volume":"6","author":"LA Kingsley","year":"2007","unstructured":"Kingsley LA, Fournier PG, Chirgwin JM, Guise TA (2007) Molecular biology of bone metastasis. Mol Cancer Ther 6(10):2609\u20132617","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"3290_CR4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10549-012-2222-2","volume":"135","author":"J Canon","year":"2012","unstructured":"Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC (2012) RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 135(3):771\u2013780","journal-title":"Breast Cancer Res Treat"},{"issue":"12 Suppl","key":"3290_CR5","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","volume":"88","author":"TA Guise","year":"2000","unstructured":"Guise TA (2000) Molecular mechanisms of osteolytic bone metastases. Cancer 88(12 Suppl):2892\u20132898","journal-title":"Cancer"},{"issue":"1","key":"3290_CR6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","volume":"34","author":"GD Roodman","year":"2008","unstructured":"Roodman GD, Dougall WC (2008) RANK ligand as a therapeutic target for bone metastases and multiple myeloma. Cancer Treat Rev 34(1):92\u2013101","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"3290_CR7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","volume":"17","author":"T Nakashima","year":"2011","unstructured":"Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T (2011) Homeostasis through RANKL expression. Nat Med 17(10):1231\u20131234","journal-title":"Nat Med"},{"issue":"6937","key":"3290_CR8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423(6937):337\u2013342","journal-title":"Nature"},{"issue":"5484","key":"3290_CR9","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","volume":"289","author":"SL Teitelbaum","year":"2000","unstructured":"Teitelbaum SL (2000) Bone resorption by osteoclasts. Science 289(5484):1504\u20131508","journal-title":"Science"},{"issue":"8","key":"3290_CR10","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/j.0022-0337.2008.72.8.tb04568.x","volume":"72","author":"A Mariotti","year":"2008","unstructured":"Mariotti A (2008) Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 72(8):919\u2013929","journal-title":"J Dent Educ"},{"issue":"9773","key":"3290_CR11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S0140-6736(10)62349-5","volume":"377","author":"TD Rachner","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC (2011) Osteoporosis: now and the future. Lancet 377(9773):1276\u20131287","journal-title":"Lancet"},{"issue":"5484","key":"3290_CR12","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","volume":"289","author":"GA Rodan","year":"2000","unstructured":"Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508\u20131514","journal-title":"Science"},{"issue":"7","key":"3290_CR13","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.mp.4002064","volume":"13","author":"L Xiao","year":"2008","unstructured":"Xiao L, Xu H, Zhang Y, Wei Z, He J, Jiang W, Li X, Dyck LE, Devon RM, Deng Y, Li XM (2008) Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes. Mol Psychiatr 13(7):697\u2013708","journal-title":"Mol Psychiatr"},{"issue":"1\u20133","key":"3290_CR14","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejphar.2011.12.017","volume":"678","author":"H Kim","year":"2012","unstructured":"Kim H, Bang J, Chang HW, Kim JY, Park KU, Kim SH, Lee KJ, Cho CH, Hwang I, Park SD, Ha E, Jung SW (2012) Anti-inflammatory effect of quetiapine on collagen-induced arthritis of mouse. Eur J Pharmacol 678(1\u20133):55\u201360","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"3290_CR15","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1111\/j.1742-4658.2008.06519.x","volume":"275","author":"H Xu","year":"2008","unstructured":"Xu H, Wang H, Zhuang L, Yan B, Yu Y, Wei Z, Zhang Y, Dyck LE, Richardson SJ, He J, Li X, Kong J, Li XM (2008) Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer\u2019s disease. FEBS J 275(14):3718\u20133728","journal-title":"FEBS J"},{"issue":"2","key":"3290_CR16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1179\/174313209X393573","volume":"31","author":"X Bi","year":"2009","unstructured":"Bi X, Yan B, Fang S, Yang Y, He J, Li XM, Kong J (2009) Quetiapine regulates neurogenesis in ischemic mice by inhibiting NF-kappaB p65\/p50 expression. Neurol Res 31(2):159\u2013166","journal-title":"Neurol Res"},{"issue":"1","key":"3290_CR17","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2202-15-30","volume":"15","author":"A Pereira","year":"2014","unstructured":"Pereira A, Zhang B, Malcolm P, Sugiharto-Winarno A, Sundram S (2014) Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor. BMC Neurosci 15(1):30","journal-title":"BMC Neurosci"},{"issue":"8","key":"3290_CR18","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrg1122","volume":"4","author":"SL Teitelbaum","year":"2003","unstructured":"Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4(8):638\u2013649","journal-title":"Nat Rev Genet"},{"issue":"8","key":"3290_CR19","doi-asserted-by":"crossref","first-page":"e42746","DOI":"10.1371\/journal.pone.0042746","volume":"7","author":"F Mei","year":"2012","unstructured":"Mei F, Guo S, He Y, Wang L, Wang H, Niu J, Kong J, Li X, Wu Y, Xiao L (2012) Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation. PLoS ONE 7(8):e42746","journal-title":"PLoS ONE"},{"issue":"9","key":"3290_CR20","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1210\/endo.142.9.8402","volume":"142","author":"DM Huber","year":"2001","unstructured":"Huber DM, Bendixen AC, Pathrose P, Srivastava S, Dienger KM, Shevde NK, Pike JW (2001) Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology 142(9):3800\u20133808","journal-title":"Endocrinology"},{"issue":"38","key":"3290_CR21","doi-asserted-by":"crossref","first-page":"33084","DOI":"10.1074\/jbc.M111.235937","volume":"286","author":"KM Remen","year":"2011","unstructured":"Remen KM, Henning P, Lerner UH, Gustafsson JA, Andersson G (2011) Activation of liver X receptor (LXR) inhibits receptor activator of nuclear factor kappaB ligand (RANKL)-induced osteoclast differentiation in an LXRbeta-dependent mechanism. J Biol Chem 286(38):33084\u201333094","journal-title":"J Biol Chem"},{"key":"3290_CR22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/0470846658.ch16","volume":"232","author":"T Suda","year":"2001","unstructured":"Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N (2001) The molecular basis of osteoclast differentiation and activation. Novartis Found Symp 232:235\u2013247 (discussion 247-250)","journal-title":"Novartis Found Symp"},{"issue":"5","key":"3290_CR23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/jcp.24259","volume":"228","author":"SC Gannon","year":"2013","unstructured":"Gannon SC, Cantley MD, Haynes DR, Hirsch R, Bartold PM (2013) Azithromycin suppresses human osteoclast formation and activity in vitro. J Cell Physiol 228(5):1098\u20131107","journal-title":"J Cell Physiol"},{"issue":"1","key":"3290_CR24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-014-2844-7","volume":"144","author":"Z Zhai","year":"2014","unstructured":"Zhai Z, Qu X, Yan W, Li H, Liu G, Liu X, Tang T, Qin A, Dai K (2014) Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling. Breast Cancer Res Treat 144(1):33\u201345","journal-title":"Breast Cancer Res Treat"},{"issue":"20 Pt 2","key":"3290_CR25","doi-asserted-by":"crossref","first-page":"6213s","DOI":"10.1158\/1078-0432.CCR-06-1007","volume":"12","author":"TA Guise","year":"2006","unstructured":"Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM (2006) Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12(20 Pt 2):6213s\u20136216s","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3290_CR26","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD (2004) Mechanisms of bone metastasis. New Engl J Med 350(16):1655\u20131664","journal-title":"New Engl J Med"},{"issue":"Suppl","key":"3290_CR27","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/S0092-8674(02)00703-1","volume":"109","author":"S Ghosh","year":"2002","unstructured":"Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81\u201396","journal-title":"Cell"},{"issue":"3 Suppl","key":"3290_CR28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/COC.0b013e3181deb9e5","volume":"33","author":"A Lipton","year":"2010","unstructured":"Lipton A (2010) Bone continuum of cancer. Am J Clin Oncol 33(3 Suppl):S1\u20137","journal-title":"Am J Clin Oncol"},{"key":"3290_CR29","doi-asserted-by":"crossref","unstructured":"Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. The Cochrane database of systematic reviews 2:CD003474","DOI":"10.1002\/14651858.CD003474.pub3"},{"issue":"3","key":"3290_CR30","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0935-7","volume":"122","author":"A Lipton","year":"2010","unstructured":"Lipton A (2010) Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res Treat 122(3):627\u2013636","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"3290_CR31","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/j.1875-9114.2011.01092.x","volume":"32","author":"M Iranikhah","year":"2012","unstructured":"Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB (2012) Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. Pharmacotherapy 32(3):274\u2013284","journal-title":"Pharmacotherapy"},{"issue":"25","key":"3290_CR32","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1056\/NEJMe1010459","volume":"363","author":"A Grey","year":"2010","unstructured":"Grey A (2010) Teriparatide for bone loss in the jaw. N Engl J Med 363(25):2458\u20132459","journal-title":"N Engl J Med"},{"issue":"3","key":"3290_CR33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02411252","volume":"34","author":"C Minkin","year":"1982","unstructured":"Minkin C (1982) Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 34(3):285\u2013290","journal-title":"Calcif Tissue Int"},{"issue":"4","key":"3290_CR34","first-page":"308","volume":"17","author":"GD Roodman","year":"1996","unstructured":"Roodman GD (1996) Advances in bone biology: the osteoclast. Endocr Rev 17(4):308\u2013332","journal-title":"Endocr Rev"},{"issue":"5","key":"3290_CR35","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1600-0765.2008.01168.x","volume":"44","author":"F Grases","year":"2009","unstructured":"Grases F, Perello J, Sanchis P, Isern B, Prieto RM, Costa-Bauza A, Santiago C, Ferragut ML, Frontera G (2009) Anticalculus effect of a triclosan mouthwash containing phytate: a double-blind, randomized, three-period crossover trial. J Periodontal Res 44(5):616\u2013621","journal-title":"J Periodontal Res"},{"issue":"40","key":"3290_CR36","doi-asserted-by":"crossref","first-page":"31155","DOI":"10.1074\/jbc.M001229200","volume":"275","author":"M Matsumoto","year":"2000","unstructured":"Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 275(40):31155\u201331161","journal-title":"J Biol Chem"},{"issue":"4","key":"3290_CR37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1172\/JCI200419657","volume":"114","author":"F Ikeda","year":"2004","unstructured":"Ikeda F, Nishimura R, Matsubara T, Tanaka S, Inoue J, Reddy SV, Hata K, Yamashita K, Hiraga T, Watanabe T, Kukita T, Yoshioka K, Rao A, Yoneda T (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest 114(4):475\u2013484","journal-title":"J Clin Invest"},{"issue":"42","key":"3290_CR38","doi-asserted-by":"crossref","first-page":"35081","DOI":"10.1074\/jbc.C500353200","volume":"280","author":"P Monje","year":"2005","unstructured":"Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD, Gutkind JS (2005) Regulation of the t ranscriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 280(42):35081\u201335084","journal-title":"J Biol Chem"},{"issue":"1","key":"3290_CR39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bone.2013.01.041","volume":"54","author":"X Lu","year":"2013","unstructured":"Lu X, Ito Y, Atsawasuwan P, Dangaria S, Yan X, Wu T, Evans CA, Luan X (2013) Ameloblastin modulates osteoclastogenesis through the integrin\/ERK pathway. Bone 54(1):157\u2013168","journal-title":"Bone"},{"issue":"5","key":"3290_CR40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.biocel.2009.12.018","volume":"42","author":"Q Zhao","year":"2010","unstructured":"Zhao Q, Wang X, Liu Y, He A, Jia R (2010) NFATc1: functions in osteoclasts. Int J Biochem Cell Biol 42(5):576\u2013579","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"3290_CR41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1535-7163.MCT-11-0731","volume":"11","author":"B Sung","year":"2012","unstructured":"Sung B, Oyajobi B, Aggarwal BB (2012) Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling. Mol Cancer Ther 11(2):350\u2013359","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3290_CR42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/nrd1279","volume":"3","author":"M Karin","year":"2004","unstructured":"Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discovery 3(1):17\u201326","journal-title":"Nat Rev Drug Discovery"},{"issue":"Suppl 13","key":"3290_CR43","first-page":"5","volume":"63","author":"CB Nemeroff","year":"2002","unstructured":"Nemeroff CB, Kinkead B, Goldstein J (2002) Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiat 63(Suppl 13):5\u201311","journal-title":"J Clin Psychiat"},{"key":"3290_CR44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2202-15-30","volume":"15","author":"A Pereira","year":"2014","unstructured":"Pereira A, Zhang B, Malcolm P, Sugiharto-Winarno A, Sundram S (2014) Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor. BMC Neurosci 15:30","journal-title":"BMC Neurosci"},{"issue":"2","key":"3290_CR45","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/jcp.21511","volume":"217","author":"T Yi","year":"2008","unstructured":"Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH (2008) Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling. J Cell Physiol 217(2):409\u2013422","journal-title":"J Cell Physiol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3290-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-015-3290-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-015-3290-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T04:33:30Z","timestamp":1598934810000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-015-3290-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["3290"],"URL":"https:\/\/doi.org\/10.1007\/s10549-015-3290-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}